Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.190
+0.200 (5.01%)
At close: Nov 21, 2025, 4:00 PM EST
4.180
-0.010 (-0.24%)
After-hours: Nov 21, 2025, 7:43 PM EST
Taysha Gene Therapies Stock Forecast
Stock Price Forecast
The 9 analysts that cover Taysha Gene Therapies stock have a consensus rating of "Strong Buy" and an average price target of $10.22, which forecasts a 143.91% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $14.
Price Target: $10.22 (+143.91%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Taysha Gene Therapies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 5 | 5 |
| Buy | 4 | 2 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 7 | 7 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $6 → $8 | Buy | Maintains | $6 → $8 | +90.93% | Nov 5, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +186.40% | Nov 5, 2025 |
| Raymond James | Raymond James | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | +210.26% | Oct 21, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +186.40% | Oct 17, 2025 |
| Needham | Needham | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +138.66% | Oct 17, 2025 |
Financial Forecast
Revenue This Year
7.67M
from 8.33M
Decreased by -7.94%
Revenue Next Year
4.17M
from 7.67M
Decreased by -45.68%
EPS This Year
-0.36
from -0.36
EPS Next Year
-0.42
from -0.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.8M | 15.8M | |||
| Avg | 7.7M | 4.2M | |||
| Low | 4.2M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 89.0% | 105.3% | |||
| Avg | -7.9% | -45.7% | |||
| Low | -49.6% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.34 | -0.37 | |||
| Avg | -0.36 | -0.42 | |||
| Low | -0.38 | -0.55 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.